TEST-RETEST RELIABILITY OF AN INTERACTIVE VOICE RESPONSE (IVR) VERSION OF THE EQ-5D IN A SAMPLE OF CANCER SURVIVORS
Author(s)
J. Jason Lundy, PhD, Graduate Student, Stephen Joel Coons, PhD, ProfessorUniversity of Arizona, Tucson, AZ, USA
OBJECTIVES The objective of this study was to assess the test-retest reliability of an interactive voice response (IVR) version of the EQ-5D. METHODS The EQ-5D self-report questionnaire consists of a descriptive system and a visual analog scale (EQ VAS). Responses on the descriptive system classify the respondent into one of 243 unique health states. A preference weight is assigned to the health state, resulting in an EQ-5D index score on a scale where 1 = perfect health and 0 = death. Cancer clinic patients (n=127) were asked to complete the IVR-based EQ-5D twice, two days apart. The analyses tested for mean differences (paired t-test) and test-retest reliability (ICC) to assess measurement stability over time. Equivalence of the means was established if the 95% confidence interval (CI) was within the minimally important difference (MID) interval, namely -.025 to .025 for the index and -3 to 3 for the EQ-VAS. Adequacy of the ICC was established by comparing the ICC 95% lower CI with a critical value of 0.70. RESULTS Both administrations were completed per protocol by 110 subjects (EQ-5D index) and 114 subjects (EQ VAS). For the EQ-5D index, the means (SD) of the first and second administrations were 0.871 (0.138) and 0.868 (0.153), respectively. The 95% CI of the mean difference was -0.012 to 0.017, which was within the equivalence interval. The ICC was 0.858 (0.800 – 0.901) and was significantly different from 0.70 (p<0.001). For the EQ VAS, the means (SD) were 81.34 (17.46) and 80.83 (17.52), respectively. The 95% CI of the mean difference was -0.598 to 1.617, which was within the equivalence interval. The ICC was 0.944 (0.919 – 0.961) and was significantly different from 0.70 (p<0.001). CONCLUSIONS This analysis provides substantial evidence that the scores obtained from the IVR version of the EQ-5D are reliable upon repeated administrations.
Conference/Value in Health Info
2009-05, ISPOR 2009, Orlando, FL, USA
Value in Health, Vol. 12, No. 3 (May 2009)
Code
PCN86
Disease
Oncology